Medication Guide App

Ibandronate Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Osteoporosis

2.5 mg orally once daily
150 mg orally once monthly on the same day each month
3 mg by bolus intravenous injection over 15 to 30 seconds every three months.

Duration: For patients at low risk for fracture, consider discontinuation after 3 to 5 years of treatment. An optimum duration of treatment has not been determined.

Comments:
Oral ibandronate should be administered with 6 to 8 ounces of plain water at least 60 minutes before the first food, beverage or medication of the day. Beverages other than water, food, and certain medications reduce the absorption of ibandronate. Plain water is the only drink that should be taken with ibandronate. Some mineral waters may have a higher concentration of calcium and therefore should not be used.

Patients should remain upright (standing or sitting) for at least 60 minutes following administration of oral ibandronate.

Usual Adult Dose for Prevention of Osteoporosis

2.5 mg orally once daily
150 mg orally once monthly on the same day each month
3 mg by bolus intravenous injection over 15 to 30 seconds every three months.

Duration: For patients at low risk for fracture, consider discontinuation after 3 to 5 years of treatment. An optimum duration of treatment has not been determined.

Comments:
Oral ibandronate should be administered with 6 to 8 ounces of plain water at least 60 minutes before the first food, beverage or medication of the day. Beverages other than water, food, and certain medications reduce the absorption of ibandronate. Plain water is the only drink that should be taken with ibandronate. Some mineral waters may have a higher concentration of calcium and therefore should not be used.

Patients should remain upright (standing or sitting) for at least 60 minutes following administration of oral ibandronate.

Renal Dose Adjustments

The renal clearance of ibandronate is decreased as much as 70% in patients with creatinine clearance of approximately 30 mL/min. The use of ibandronate is not recommended in patients with this degree of renal dysfunction.

Liver Dose Adjustments

There are no data on the pharmacokinetic disposition of ibandronate in patients with liver dysfunction since ibandronate is not metabolized in the human liver.

Precautions

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Hide
(web2)